ASCO 2017 - Lung Cancer - Improved Progression-Free Survival with Iressa as Adjuvant Therapy for EGFR Patients

Article and Video CATEGORIES

Cancer Journey

ABOUT

Howard Jack West, MD, Founder, Board President

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

ASCO 2017 - Lung Cancer - Improved Progression-Free Survival with Iressa as Adjuvant Therapy for EGFR Patients

Anonymous

Fri, 08/11/2017 - 08:00

Author

Howard (Jack) West, MD

Drs. H. Jack West, Medical Director of the Thoracic Oncology Program at Swedish Cancer Institute in Seattle, Washington and President and CEO of GRACE, Matthew Gubens, Thoracic Oncologist at the Thoracic Surgery and Oncology Clinic of the UCSF Helen Diller Family Comprehensive Center in San Francisco, California, and Jyoti Patel, Director of Thoracic Oncology at University of Chicago Medicine gathered post meeting to discuss new information from ASCO 2017 regarding lung cancer. In this roundtable video, the doctors discuss Improved Progression-Free Survival with Iressa as Adjuvant Therapy for EGFR Mutation Positive Patients and Why That Doesn't Change Anything.

GRACE would like to thank the following sponsors for their support of this program

Next Previous link

Previous Post Next Post

Related Content

Videoteca de Cáncer de Pulmón en Español 2025

Video

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.

Unlocking Precision in Lung Cancer: Understanding and Overcoming Resistance to EGFR and ALK Inhibitors

Article

The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.

2025 Rare Cancers Patient Education Library

Video

In these videos, Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment. To watch the complete playlist, click here.